Skip to main navigation

Investor Relations

December 01, 2021

Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis

November 30, 2021

Abivax’s phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Symposium 2022

October 18, 2021

ABX464 shows excellent long-term efficacy data in Abivax’s phase 2b maintenance trial in ulcerative colitis

September 30, 2021

Abivax announces the release of its half-year financial report 2021

September 28, 2021

Abivax late-breaking abstract presentation and Live Industry Symposium at UEG Week Virtual 2021